BioAuxilium Research Launches New THUNDER™ TR-FRET Biomarker Assay Kits and an Enhanced Assay Development Service for Drug Discovery
SAN DIEGO–(BUSINESS WIRE)– At the annual Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in San Diego, BioAuxilium Research Inc., a biotech tool company focused on facilitating access to fully validated assay kits to the biomedical research community, today announced the expansion of its no-wash THUNDER™ time-resolved Förster resonance energy transfer (TR-FRET) technology portfolio by introducing six new biomarker research assay kits, a Reader Control Kit, and an enhanced assay development service for drug discovery research.
BioAuxilium developed the new biomarker assays in response to customer requests for reliable cell-based assays that provide an alternative to expensive immunoassay platforms such as other TR‑FRET and bead-based assay technologies. The new offerings include a panel of six key mouse inflammatory cytokines (CCL-2/MCP1, IFN-beta, IFN-gamma, IL-2, IL-6, and TNF-alpha), expanding the company’s portfolio to a total of 100 cell-based assay kits (76 Cell Signaling Kinases, 23 Biomarkers, and a cAMP Assay). The ready-to-use Reader Control Kit allows users to assess in just 10 minutes the suitability of TR‑FRET compatible microplate readers to perform Europium-based TR-FRET measurements.
The new assay development service offers three types of custom assay solutions: labeling of antibodies with BioAuxilium’s proprietary TR-FRET fluorophores, custom assay development services, and custom kit development services. These comprehensive, yet flexible custom solutions are designed to fast-track assay development, while further reducing risk, turnaround time, and cost.
“BioAuxilium continues to make great strides with the expansion of the THUNDER™ TR-FRET technology portfolio, based on customer demand for high-performing, reliable yet affordable immunoassays,” said Jaime Padros, PhD, President, BioAuxilium Research. “In addition, our decades of experience developing and manufacturing drug discovery assays based on TR-FRET allow us to deliver results within turnaround times and at prices simply unattainable by any other custom assay development service.”
BioAuxilium’s THUNDER™ TR-FRET technology is a robust, proprietary platform based on a FRET pair showing an enhanced spectral compatibility and TR-FRET signal, best antibody pairs selected specifically for TR-FRET, and a panel of optimized lysis and assay buffers. In addition, the “add-incubate-read” protocol of the immunoassay platform, combined with its full compatibility with different TR-FRET readers, facilitates streamlined workflows and automation for high-throughput screening. All THUNDER™ TR-FRET assays are extensively validated to ensure specificity, sensitivity, reproducibility, and lot-to-lot consistency.
About BioAuxilium Research Inc.
BioAuxilium is a private Canadian biotechnology tool company founded by expert assay scientists. It focuses on developing and manufacturing top-quality, highly validated assay kits that accelerate drug discovery and basic research. BioAuxilium’s kits are based on its enhanced proprietary THUNDER™ TR‑FRET technology. They are offered at an outstanding value and are accompanied by information-rich datasheets and expert technical support. BioAuxilium also provides customized services in assay development on a contract basis. Their products and services are available directly to US- and Canada-based customers, and through the company’s network of international distributors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005027/en/
Jaime Padros, President
514-312-9033 ext. 101